THE USE OF THE AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 FOR REVACCINATION OF POPULATION (VARIANTS)

The group of inventions relates to the field of biotechnology, immunology and virology. The use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 26 with El and E3 site...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	NARODITSKY, BORIS SAVELIEVICH, LOGUNOV, DENIS YURYEVICH, ESMAGAMBETOV, ILIAS BULATOVICH, LUBENETS, NADEZHDA LEONIDOVNA, DZHARULLAEVA, ALINA SHAHMIROVNA, SEMIKHIN, ALEKSANDR SERGEEVICH, POPOVA, OLGA, KUTAEV, DMITRII ANATOLEVICH, TUKHVATULINA, NATALIA MIKHAILOVNA, EROXOVA, ALINA SERGEEVNA, SHCHERBININ, DMITRII NIKOLAEVICH, LOGINOVA, SVETLANA IAKOVLEVNA, GINTSBURG, ALEKSANDR LEONIDOVICH, NIKITENKO, NATALYA ANATOLEVNA, OZHAROVSKAIA, TATIANA ANDREEVNA, BABIRA, VALDIMIR FEDOROVICH, CHERNETSOV, VLADIMIR ALEKSANDROVICH, GROUSOVA, DARIA MIKHAILOVNA, DOLZHIKOVA, INNA VADIMOVNA, BOTIKOV, ANDREI GENNADEVICH, TUKHVATULIN, AMIR ILDAROVICH, IZHAEVA, FATIMA MAGOMETOVNA, ZUBKOVA, OLGA VADIMOVNA, TOKARSKAYA, ELIZAVETA ALEXANDROVNA, SHCHEBLIAKOV, DMITRII VIKTOROVICH, KRIUKOV, EVGENII VLADIMIROVICH
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The group of inventions relates to the field of biotechnology, immunology and virology. The use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 26 with El and E3 sites deleted from the genome, and the site ORF6-Ad26 is substituted for ORF6-Ad5 with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and/or containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 5 with El and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3. In addition an agent is used, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 26 with El and E3 sites deleted from the genome, and the site 0RF6-Ad26 is substituted for 0RF6-Ad5 with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and also containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of simian adenovirus serotype 25 with El and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3, or containing only component 2. Furthermore, an agent is used, such agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of simian adenovirus serotype 25 with El and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3, and also containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 5 with El and E3 sites deleted from the genome with the integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3. The group of invention enables to create safe and efficacious agents providing extension of postvaccinal immunity against virus SARS-CV-2, and is intended for revaccination of population against the diseases caused by severe acute respiratory syndrome virus SARS-CoV-2.